Tecentriq atezolizumab: Additional Phase Ib data

Additional data from 23 evaluable patients with colorectal cancer in an open label, international Phase Ib trial showed that 800 mg IV atezolizumab every 2 weeks plus once-daily 20-60 mg Cotellic cob...